![Belite Bio, Inc logo](/logos/BLTE.webp)
Belite Bio, Inc
NASDAQ:BLTE
Overview | Financials
Company Name | Belite Bio, Inc |
Symbol | BLTE |
Currency | USD |
Price | 48.2 |
Market Cap | 1,475,515,704 |
Dividend Yield | 0% |
52-week-range | 26.65 - 50.66 |
Industry | Biotechnology |
Sector | Healthcare |
CEO | Dr. Yu-Hsin Lin M.B.A., Ph.D. |
Website | https://belitebio.com |
An error occurred while fetching data.
About Belite Bio, Inc
Belite Bio, Inc, a clinical-stage biopharmaceutical drug development company, engages in the research and development of novel therapeutics targeting atrophic age-related macular degeneration and autosomal recessive stargardt diseases. Its lead product candidate is LBS-008, an oral once-a-day treatment that can reduce and maintain the delivery of vitamin A to the
Related Stocks
Financials
Numbers are in millions USD
Numbers are in millions USD